{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T18:10:06Z","timestamp":1788718206549,"version":"build-2803163510"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,3]],"date-time":"2020-10-03T00:00:00Z","timestamp":1601683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,3]],"date-time":"2020-10-03T00:00:00Z","timestamp":1601683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s00277-020-04294-x","type":"journal-article","created":{"date-parts":[[2020,10,3]],"date-time":"2020-10-03T06:02:31Z","timestamp":1601704951000},"page":"1-10","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Progressive multifocal leukoencephalopathy in multiple myeloma. A literature review and lessons to learn"],"prefix":"10.1007","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6379-1298","authenticated-orcid":false,"given":"Ioannis","family":"Koutsavlis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,3]]},"reference":[{"issue":"4","key":"4294_CR1","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","volume":"9","author":"CS Tan","year":"2010","unstructured":"Tan CS, Koralnik IJ (2010) Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 9(4):425\u2013437","journal-title":"Lancet Neurol"},{"issue":"15","key":"4294_CR2","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","volume":"80","author":"JR Berger","year":"2013","unstructured":"Berger JR, Aksamit AJ, Clifford DB, Davis L, Koralnik IJ, Sejvar JJ, Bartt R, Major EO, Nath A (2013) PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology 80(15):1430\u20131438","journal-title":"Neurology"},{"issue":"1","key":"4294_CR3","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s12185-010-0600-2","volume":"92","author":"M Akiyama","year":"2010","unstructured":"Akiyama M, Takahashi T, Nomura S, Yamashita Y, Hatao K (2010) Progressive multifocal leukoencephalopathy in a patient with multiple myeloma. Int J Hematol 92(1):186\u2013189","journal-title":"Int J Hematol"},{"key":"4294_CR4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/1752-1947-6-177","volume":"6","author":"M Troppmann","year":"2012","unstructured":"Troppmann M, B\u00fcttner R, Boewer M, Salzberger B (2012) Smoldering myeloma presenting as progressive multifocal leukoencephalopathy: a case report. J Med Case Rep 6:177","journal-title":"J Med Case Rep"},{"key":"4294_CR5","unstructured":"Hughes L, Butler A, Fink J (2010) Progressive multifocal leukoencephalopathy in a patient with multiple myeloma. Internal Medicine Journal. Conference: World Congress of Internal Medicine, WCIM 2010 in Conjunction with Physicians Week. Melbourne, VIC Australia. Conference Publication: (var.pagings). 40 (SUPPL. 1) (pp 104)"},{"issue":"1","key":"4294_CR6","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2463\/mrms.2013-0037","volume":"13","author":"M Mungunkhuyag","year":"2014","unstructured":"Mungunkhuyag M, Harada M, Abe T, Fujita K, Matsui N, Kaji R (2014) Longitudinal monitoring with multiple MR techniques in a case of progressive multifocal leukoencephalopathy associated with multiple myeloma. Magn Reson Med Sci 13(1):55\u201359","journal-title":"Magn Reson Med Sci"},{"issue":"4","key":"4294_CR7","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1177\/1078155218769367","volume":"25","author":"Y Ruiz-Heredia","year":"2019","unstructured":"Ruiz-Heredia Y, Sanchez-Vega B, Barrio S, Linares M, Rapado I, Braggio E, Stewart K, Folgueira MD, Ramos A, Collado L, Ruiz J, Toldos O, Hernandez-Lain A, Martinez-Lopez J (2019) Concurrent progressive multifocal leukoencephalopathy and central nervous system infiltration by multiple myeloma: a case report. J Oncol Pharm Pract 25(4):998\u20131002","journal-title":"J Oncol Pharm Pract"},{"issue":"10","key":"4294_CR8","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1080\/10428194.2017.1292355","volume":"58","author":"F Brigo","year":"2017","unstructured":"Brigo F, Pagani E, Tezzon F, Masi E, Nardone R (2017) Lenalidomide-associated progressive multifocal leukoencephalopathy. Leuk Lymphoma 58(10):2514\u20132515","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"4294_CR9","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1038\/bmt.2010.33","volume":"45","author":"L Fianchi","year":"2010","unstructured":"Fianchi L, Colosimo C, De Luca A, Pompucci A, Cattani P, Voso MT, LaRocca LM, Leone G, Pagano L (2010) Atypical presentation of progressive multifocal leukoencephalopathy in a multiple myeloma patient after auto-SCT successfully treated with combination therapy. Bone Marrow Transplant 45(11):1668\u20131670","journal-title":"Bone Marrow Transplant"},{"key":"4294_CR10","doi-asserted-by":"publisher","unstructured":"Ripellino P, Comi C, Mula M, Varrasi C, Conconi A, Stecco A, Brustia D, Nasuelli N, Savio K, De Paoli L, Cantello R, Gaidano G, Monaco F (2011) Progressive multifocal leucoencephalopathy after autologous bone marrow transplantation: a treatment option. BMJ Case Rep bcr1120103549. https:\/\/doi.org\/10.1136\/bcr.11.2010.3549","DOI":"10.1136\/bcr.11.2010.3549"},{"key":"4294_CR11","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jns.2016.07.045","volume":"368","author":"K Yokokawa","year":"2016","unstructured":"Yokokawa K, Hisahara S, Matsuura Y, Ikeda K, Tsuda E, Saitoh M, Nakamichi K, Saijo M, Kamihara Y, Sato T, Kawamata J, Shimohama S (2016) Progressive multifocal leukoencephalopathy after autologous peripheral blood stem cell transplantation in a patient with multiple myeloma treated with combination therapy. J Neurol Sci 368:304\u2013306","journal-title":"J Neurol Sci"},{"issue":"1","key":"4294_CR12","first-page":"e99","volume":"25","author":"CP Sawicki","year":"2018","unstructured":"Sawicki CP, Climans SA, Hsia CC, Fraser JA (2018) Progressive multifocal leukoencephalopathy during ixazomib-based chemotherapy. Curr Oncol (Toronto, Ont.) 25(1):e99\u2013e102","journal-title":"Curr Oncol (Toronto, Ont.)"},{"key":"4294_CR13","first-page":"1","volume":"00","author":"KM Bennett","year":"2020","unstructured":"Bennett KM, Storrar N, Johnson P, Fernandes PM (2020) Progressive multifocal leukoencephalopathy (PML) following autologous peripheral blood stem cell transplantation for multiple myeloma. Clin Case Rep 00:1\u20136","journal-title":"Clin Case Rep"},{"issue":"Supplement_1","key":"4294_CR14","doi-asserted-by":"crossref","first-page":"4876","DOI":"10.1182\/blood-2019-122134","volume":"134","author":"J Monge","year":"2019","unstructured":"Monge J, Contreras J, Elsoukkary S, Guo J, Perry A, Solomon SR, Flicker K, Jayabalan DS, Coleman M, Rossi AC, Harris R, Plate M, Stuebgen JR, Niesvizky R (2019) Progressive multifocal leukoencephalopathy in a patient with multiple myeloma receiving daratumumab and pomalidomide. Blood 134(Supplement_1):4876","journal-title":"Blood"},{"key":"4294_CR15","doi-asserted-by":"crossref","unstructured":"Aydin Y, Salihoglu A, Uygunoglu U, Keskin D, Yurttas NO, Ozmen D, Ercaliskan A, Elverdi T, Eskazan AE, Ar MC, Ongoren S, Baslar Z, Soysal T (2019) Progressive multifocal leukoencephalopathy in a patient with multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia. Conference: 17th International Myeloma Workshop. United States. 19 (10 Supplement) (pp e241)","DOI":"10.1016\/j.clml.2019.09.400"},{"issue":"15 Supplement","key":"4294_CR16","first-page":"P1.2","volume":"92","author":"S Woodson","year":"2019","unstructured":"Woodson S, Manly C, Kwok M, Smith J (2019) Progressive multifocal leukoencephalopathy in a patient with relapsed multiple myeloma: a case report and literature review. Neurology 92(15 Supplement):P1.2\u2013P029","journal-title":"Neurology"},{"issue":"3","key":"4294_CR17","doi-asserted-by":"crossref","first-page":"e233552","DOI":"10.1136\/bcr-2019-233552","volume":"13","author":"K Knight","year":"2020","unstructured":"Knight K, Chien S, Koutsavlis I, Campbell V (2020) Progressive multifocal leukoencephalopathy following five lines of therapy and three autologous bone marrow transplants for multiple myeloma. BMJ Case Rep 13(3):e233552","journal-title":"BMJ Case Rep"},{"issue":"1","key":"4294_CR18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12967-020-02337-5","volume":"18","author":"MJ Steinhardt","year":"2020","unstructured":"Steinhardt MJ, Wiercinska E, Pham M, Grigoleit GU, Mazzoni A, Da-Via M, Zhou X, Meckel K, Nickel K, Duell J, Krummenast FC, Kraus S, Hopkinson C, Weissbrich B, M\u00fcllges W, Stoll G, Kort\u00fcm KM, Einsele H, Bonig H, Rasche L (2020) Progressive multifocal leukoencephalopathy in a patient post allo-HCT successfully treated with JC virus specific donor lymphocytes. J Transl Med 18(1):177 Table 2 is a summary of the characteristics and outcome of the patients including references","journal-title":"J Transl Med"},{"issue":"12","key":"4294_CR19","doi-asserted-by":"crossref","first-page":"e625","DOI":"10.1016\/j.clml.2019.09.617","volume":"19","author":"J Yeung","year":"2019","unstructured":"Yeung J, van Hal S, Ho PJ (2019) Prolonged immunosuppression in relapsed, refractory multiple myeloma leading to cerebral toxoplasmosis and progressive multifocal leukoencephalopathy. Clin Lymphoma Myeloma Leuk 19(12):e625\u2013e628","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"4294_CR20","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1016\/j.clml.2018.12.021","volume":"19","author":"S Anderson","year":"2019","unstructured":"Anderson S, Kiernan M, Ho PJ (2019) Lenalidomide-related progressive multifocal leukoencephalopathy: a case report and review of drug-related cases in multiple myeloma. Clin Lymphoma Myeloma Leuk 19(4):e169\u2013e171","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4294_CR21","unstructured":"Willert CB, Engsig FN, Eskildsen HW, Andersen AB (2014) Ugeskrift for laeger, 176(49), V08140432"},{"issue":"4","key":"4294_CR22","first-page":"581","volume":"7","author":"H Gordon","year":"1971","unstructured":"Gordon H, Bandmann M, Sandbank U (1971) Multiple myeloma associated with progressive multifocal leukoencephalopathy and Pneumocystis carinii pneumonia. Isr J Med Sci 7(4):581\u2013588","journal-title":"Isr J Med Sci"},{"issue":"4","key":"4294_CR23","first-page":"319","volume":"131","author":"V Navarro","year":"1973","unstructured":"Navarro V, Rapado A, Capote L, Ru\u00edz F, De la Barreda P (1973) Leucoencefalopat\u00e1 multifocal progresiva en un mieloma [Progressive multifocal leukoencephalopathy in a case of myeloma]. Rev Clin Esp 131(4):319\u2013326","journal-title":"Rev Clin Esp"},{"issue":"9","key":"4294_CR24","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1001\/jama.1967.03120090113030","volume":"199","author":"V DelDuca Jr","year":"1967","unstructured":"DelDuca V Jr, Morningstar WA (1967) Multiple myeloma associated with progressive multifocal leukoencephalopathy. JAMA 199(9):671\u2013673","journal-title":"JAMA"},{"issue":"1","key":"4294_CR25","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1086\/504947","volume":"43","author":"JR Berger","year":"2006","unstructured":"Berger JR, Miller CS, Mootoor Y, Avdiushko SA, Kryscio RJ, Zhu H (2006) JC virus detection in bodily fluids: clues to transmission. Clin Infect Dis 43(1):e9\u2013e12","journal-title":"Clin Infect Dis"},{"issue":"5","key":"4294_CR26","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJM198802043180507","volume":"318","author":"SA Houff","year":"1988","unstructured":"Houff SA, Major EO, Katz DA, Kufta CV, Sever JL, Pittaluga S, Roberts JR, Gitt J, Saini N, Lux W (1988) Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy. N Engl J Med 318(5):301\u2013305","journal-title":"N Engl J Med"},{"key":"4294_CR27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1146\/annurev.med.080708.082655","volume":"61","author":"EO Major","year":"2010","unstructured":"Major EO (2010) Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 61:35\u201347","journal-title":"Annu Rev Med"},{"issue":"2","key":"4294_CR28","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","volume":"83","author":"ME Reff","year":"1994","unstructured":"Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83(2):435\u2013445","journal-title":"Blood"},{"issue":"3","key":"4294_CR29","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1128\/CMR.05031-11","volume":"25","author":"MW Ferenczy","year":"2012","unstructured":"Ferenczy MW, Marshall LJ, Nelson CD, Atwood WJ, Nath A, Khalili K, Major EO (2012) Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev 25(3):471\u2013506","journal-title":"Clin Microbiol Rev"},{"key":"4294_CR30","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3389\/fimmu.2015.00216","volume":"6","author":"E Hatchwell","year":"2015","unstructured":"Hatchwell E (2015) Is there a (host) genetic predisposition to progressive multifocal leukoencephalopathy? Front Immunol 6:216","journal-title":"Front Immunol"},{"issue":"6\u20137","key":"4294_CR31","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.imbio.2018.01.002","volume":"223","author":"D Pavlovic","year":"2018","unstructured":"Pavlovic D, Patel MA, Patera AC, Peterson I, Progressive Multifocal Leukoencephalopathy Consortium (2018) T cell deficiencies as a common risk factor for drug associated progressive multifocal leukoencephalopathy. Immunobiology 223(6\u20137):508\u2013517","journal-title":"Immunobiology"},{"key":"4294_CR32","first-page":"257","volume":"5","author":"SM Tete","year":"2014","unstructured":"Tete SM, Bijl M, Sahota SS, Bos NA (2014) Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myeloma. Front Immunol 5:257","journal-title":"Front Immunol"},{"issue":"22","key":"4294_CR33","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1182\/blood-2012-05-429415","volume":"121","author":"M Witzens-Harig","year":"2013","unstructured":"Witzens-Harig M, Hose D, J\u00fcnger S, Pfirschke C, Khandelwal N, Umansky L, Seckinger A, Conrad H, Brackertz B, R\u00e8me T, Gueckel B, Mei\u00dfner T, Hundemer M, Ho AD, Rossi JF, Neben K, Bernhard H, Goldschmidt H, Klein B, Beckhove P (2013) Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6. Blood 121(22):4493\u20134503","journal-title":"Blood"},{"issue":"1","key":"4294_CR34","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13045-016-0345-3","volume":"9","author":"C Zelle-Rieser","year":"2016","unstructured":"Zelle-Rieser C, Thangavadivel S, Biedermann R, Brunner A, Stoitzner P, Willenbacher E, Greil R, J\u00f6hrer K (2016) T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. J Hematol Oncol 9(1):116","journal-title":"J Hematol Oncol"},{"issue":"1","key":"4294_CR35","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/imr.12233","volume":"263","author":"Y Kawano","year":"2015","unstructured":"Kawano Y, Moschetta M, Manier S, Glavey S, G\u00f6rg\u00fcn GT, Roccaro AM, Anderson KC, Ghobrial IM (2015) Targeting the bone marrow microenvironment in multiple myeloma. Immunol Rev 263(1):160\u2013172","journal-title":"Immunol Rev"},{"key":"4294_CR36","doi-asserted-by":"crossref","first-page":"9271469","DOI":"10.1155\/2016\/9271469","volume":"2016","author":"G D\u2019Arena","year":"2016","unstructured":"D\u2019Arena G, Rossi G, Laurenti L, Statuto T, D\u2019Auria F, Valvano L, Simeon V, Giudice A, Innocenti I, De Feo V, Filosa R, Musto P (2016) Circulating regulatory T-cells in monoclonal gammopathies of uncertain significance and multiple myeloma: in search of a role. J Immunol Res 2016:9271469","journal-title":"J Immunol Res"},{"issue":"1","key":"4294_CR37","doi-asserted-by":"crossref","first-page":"e000286","DOI":"10.1136\/jitc-2019-000286","volume":"8","author":"BA Derman","year":"2020","unstructured":"Derman BA, Zha Y, Zimmerman TM, Malloy R, Jakubowiak A, Bishop MR, MD, & Kline, J. (2020) Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study. J Iimmunotherapy Cancer 8(1):e000286","journal-title":"J Iimmunotherapy Cancer"},{"issue":"4","key":"4294_CR38","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3109\/10428194.2012.728597","volume":"54","author":"YX Zhu","year":"2013","unstructured":"Zhu YX, Kortuem KM, Stewart AK (2013) Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma 54(4):683\u2013687","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"4294_CR39","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","volume":"128","author":"J Krejcik","year":"2016","unstructured":"Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, Syed K, Liu K, van de Donk NW, Weiss BM, Ahmadi T, Lokhorst HM, Mutis T, Sasser AK (2016) Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood 128(3):384\u2013394","journal-title":"Blood"},{"issue":"28","key":"4294_CR40","doi-asserted-by":"crossref","first-page":"46593","DOI":"10.18632\/oncotarget.16235","volume":"8","author":"L Ying","year":"2017","unstructured":"Ying L, YinHui T, Yunliang Z, Sun H (2017) Lenalidomide and the risk of serious infection in patients with multiple myeloma: a systematic review and meta-analysis. Oncotarget 8(28):46593\u201346600","journal-title":"Oncotarget"},{"issue":"2","key":"4294_CR41","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/fcp.12247","volume":"31","author":"O Colin","year":"2017","unstructured":"Colin O, Favreli\u00e8re S, Quillet A, Neau JP, Houeto JL, Lafay-Chebassier C, P\u00e9rault-Pochat MC, French Pharmacovigilance Network (2017) Drug-induced progressive multifocal leukoencephalopathy: a case\/noncase study in the French pharmacovigilance database. Fundam Clin Pharmacol 31(2):237\u2013244","journal-title":"Fundam Clin Pharmacol"},{"issue":"2","key":"4294_CR42","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/clinids\/23.2.402","volume":"23","author":"D Seong","year":"1996","unstructured":"Seong D, Bruner JM, Lee KH, Mirza N, Kwon BD, Lee JH, Lee YY, Ro J, Talpaz M, Champlin R, Deisseroth AB (1996) Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation in a patient with chronic myelogenous leukemia. Clin Infect Dis 23(2):402\u2013403","journal-title":"Clin Infect Dis"},{"issue":"3","key":"4294_CR43","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/pbc.22819","volume":"56","author":"K Fukuoka","year":"2011","unstructured":"Fukuoka K, Kaneko T, Akiyama M (2011) Progressive multifocal leukoencephalopathy in a 16-year-old patient with pancytopenia after autologous bone marrow transplantation for relapsed Hodgkin lymphoma. Pediatr Blood Cancer 56(3):507\u2013508","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"4294_CR44","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/sj.bmt.1701568","volume":"23","author":"D Re","year":"1999","unstructured":"Re D, Bamborschke S, Feiden W, Schr\u00f6der R, Lehrke R, Diehl V, Tesch H (1999) Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation and alpha-interferon immunotherapy. Bone Marrow Transplant 23(3):295\u2013298","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"4294_CR45","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1212\/WNL.54.3.743","volume":"54","author":"C Power","year":"2000","unstructured":"Power C, Gladden JG, Halliday W, Del Bigio MR, Nath A, Ni W, Major EO, Blanchard J, Mowat M (2000) AIDS- and non-AIDS-related PML association with distinct p53 polymorphism. Neurology 54(3):743\u2013746","journal-title":"Neurology"},{"key":"4294_CR46","first-page":"717919","volume":"2014","author":"PJ Teoh","year":"2014","unstructured":"Teoh PJ, Chng WJ (2014) p53 abnormalities and potential therapeutic targeting in multiple myeloma. Biomed Res Int 2014:717919","journal-title":"Biomed Res Int"},{"key":"4294_CR47","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3389\/fneur.2020.00186","volume":"11","author":"PS Eis","year":"2020","unstructured":"Eis PS, Bruno CD, Richmond TA, Koralnik IJ, Hanson BA, Major EO, Chow CR, Hendel-Chavez H, Stankoff B, Gasnault J, Taoufik Y, Hatchwell E (2020) Germline genetic risk variants for progressive multifocal leukoencephalopathy. Front Neurol 11:186","journal-title":"Front Neurol"},{"issue":"23","key":"4294_CR48","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/bloodadvances.2017008201","volume":"1","author":"EC Neil","year":"2017","unstructured":"Neil EC, DeAngelis LM (2017) Progressive multifocal leukoencephalopathy and hematologic malignancies: a single cancer center retrospective review. Blood Adv 1(23):2041\u20132045","journal-title":"Blood Adv"},{"key":"4294_CR49","doi-asserted-by":"crossref","first-page":"S153","DOI":"10.1016\/j.bbmt.2015.11.505","volume":"22","author":"AKA Raajasekar","year":"2016","unstructured":"Raajasekar AKA, Ayyapan S, Khan H, Mantzaris I, Janakiramet M (2016) Progressive multifocal leukoencephalopathy associated with hematopoietic stem cell transplant (HSCT) has better prognosis than PML associated with monoclonal antibodies or chemotherapy in hematological malignancies: analysis of a case series. Biol Blood Marrow Transplant 22:S153\u2013S154","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"4294_CR50","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/acn3.114","volume":"1","author":"T Dong-Si","year":"2014","unstructured":"Dong-Si T, Richman S, Wattjes MP, Wenten M, Gheuens S, Philip J, Datta S, McIninch J, Bozic C, Bloomgren G, Richert N (2014) Outcome and survival of asymptomatic PML in natalizumab-treated MS patients. Ann Clini Transl Neurol 1(10):755\u2013764","journal-title":"Ann Clini Transl Neurol"},{"issue":"14","key":"4294_CR51","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1097\/QAD.0b013e32830a5043","volume":"22","author":"A De Luca","year":"2008","unstructured":"De Luca A, Ammassari A, Pezzotti P, Cinque P, Gasnault J, Berenguer J, Di Giambenedetto S, Cingolani A, Taoufik Y, Miralles P, Marra CM, Antinori A, Gesida 9\/99, IRINA, ACTG 363 Study Groups (2008) Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis. AIDS (London, England) 22(14):1759\u20131767","journal-title":"AIDS (London, England)"},{"issue":"19","key":"4294_CR52","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1212\/WNL.0b013e3181c0d4a1","volume":"73","author":"A Marzocchetti","year":"2009","unstructured":"Marzocchetti A, Tompkins T, Clifford DB, Gandhi RT, Kesari S, Berger JR, Simpson DM, Prosperi M, De Luca A, Koralnik IJ (2009) Determinants of survival in progressive multifocal leukoencephalopathy. Neurology 73(19):1551\u20131558","journal-title":"Neurology"},{"issue":"5700","key":"4294_CR53","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1126\/science.1103492","volume":"306","author":"GF Elphick","year":"2004","unstructured":"Elphick GF, Querbes W, Jordan JA, Gee GV, Eash S, Manley K, Dugan A, Stanifer M, Bhatnagar A, Kroeze WK, Roth BL, Atwood WJ (2004) The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science (New York, N.Y.) 306(5700):1380\u20131383","journal-title":"Science (New York, N.Y.)"},{"issue":"5","key":"4294_CR54","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1128\/AAC.01614-08","volume":"53","author":"M Brickelmaier","year":"2009","unstructured":"Brickelmaier M, Lugovskoy A, Kartikeyan R, Reviriego-Mendoza MM, Allaire N, Simon K, Frisque RJ, Gorelik L (2009) Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother 53(5):1840\u20131849","journal-title":"Antimicrob Agents Chemother"},{"key":"4294_CR55","doi-asserted-by":"crossref","first-page":"116","DOI":"10.4172\/2476-213X.1000116","volume":"2","author":"H Yoshida","year":"2017","unstructured":"Yoshida H, Masaie H, Hino A, Ishikawa J (2017) A new therapeutic option for progressive multifocal leukoencephalopathy after allogeneic hematopoietic cell transplantation. J Clin Infect Dis Pract 2:116","journal-title":"J Clin Infect Dis Pract"},{"issue":"17","key":"4294_CR56","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa1815039","volume":"380","author":"I Cortese","year":"2019","unstructured":"Cortese I, Muranski P, Enose-Akahata Y, Ha SK, Smith B, Monaco M, Ryschkewitsch C, Major EO, Ohayon J, Schindler MK, Beck E, Reoma LB, Jacobson S, Reich DS, Nath A (2019) Pembrolizumab treatment for progressive multifocal leukoencephalopathy. N Engl J Med 380(17):1597\u20131605","journal-title":"N Engl J Med"},{"key":"4294_CR57","first-page":"A31","volume":"24","author":"AF Gasc\u00f3","year":"2017","unstructured":"Gasc\u00f3 AF, Vericat JM, Albir MJ, Robles GAA, Puigcerver CF, L\u00f3pez OB, Meg\u00eda MJF, Miralles FCP, Andr\u00e9s JLP, Estruch BC (2017) CP-070 interleukin-2 treatment of two patients with multifocal progressive leukoencephalopathy associated with HIV infection. Eur J Hosp Pharm 24:A31","journal-title":"Eur J Hosp Pharm"},{"issue":"3","key":"4294_CR58","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/1756285615621029","volume":"9","author":"D Dubey","year":"2016","unstructured":"Dubey D, Zhang Y, Graves D, DeSena AD, Frohman E, Greenberg B (2016) Use of interleukin-2 for management of natalizumab-associated progressive multifocal leukoencephalopathy: case report and review of literature. Ther Adv Neurol Disord 9(3):211\u2013215","journal-title":"Ther Adv Neurol Disord"},{"issue":"15","key":"4294_CR59","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1056\/NEJMoa1801540","volume":"379","author":"M Muftuoglu","year":"2018","unstructured":"Muftuoglu M, Olson A, Marin D, Ahmed S, Mulanovich V, Tummala S, Chi TL, Ferrajoli A, Kaur I, Li L, Champlin R, Shpall EJ, Rezvani K (2018) Allogeneic BK virus-specific T cells for progressive multifocal leukoencephalopathy. N Engl J Med 379(15):1443\u20131451","journal-title":"N Engl J Med"},{"issue":"20","key":"4294_CR60","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","volume":"366","author":"G Bloomgren","year":"2012","unstructured":"Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C (2012) Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 366(20):1870\u20131880","journal-title":"N Engl J Med"},{"issue":"4","key":"4294_CR61","first-page":"533","volume":"22","author":"JR Berger","year":"2016","unstructured":"Berger JR, Fox RJ (2016) Reassessing the risk of natalizumab-associated PML. J Neuro-Oncol 22(4):533\u2013535","journal-title":"J Neuro-Oncol"},{"issue":"6","key":"4294_CR62","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","volume":"76","author":"T Plavina","year":"2014","unstructured":"Plavina T, Subramanyam M, Bloomgren G, Richman S, Pace A, Lee S, Schlain B, Campagnolo D, Belachew S, Ticho B (2014) Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 76(6):802\u2013812","journal-title":"Ann Neurol"},{"issue":"3","key":"4294_CR63","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/ana.410440309","volume":"44","author":"JR Berger","year":"1998","unstructured":"Berger JR, Levy RM, Flomenhoft D, Dobbs M (1998) Predictive factors for prolonged survival in acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy. Ann Neurol 44(3):341\u2013349","journal-title":"Ann Neurol"},{"issue":"6","key":"4294_CR64","first-page":"637","volume":"21","author":"T Dong-Si","year":"2015","unstructured":"Dong-Si T, Gheuens S, Gangadharan A, Wenten M, Philip J, McIninch J, Datta S, Richert N, Bozic C, Bloomgren G, Richman S, Weber T, Clifford DB (2015) Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy. J Neuro-Oncol 21(6):637\u2013644","journal-title":"J Neuro-Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04294-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-020-04294-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04294-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T20:14:59Z","timestamp":1633378499000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-020-04294-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,3]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["4294"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-04294-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,3]]},"assertion":[{"value":"17 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The author declares that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}